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Lung cancer is the most common worldwide cause of cancer-related death. This type 
of cancer is divided into two subtypes, the small cell and non-small cell lung cancer. Platinum-
based chemotherapy is the mainstay of treatment of advanced stages non-small cell lung 
cancer, to that is this work focused on. The aim of this study was to investigate whether it is 
possible to use the comet assay method for monitoring the progress of treatment in these 
patients, and if it is possible to predict a patient's response to treatment or patient's survival. 
Standard version or modifications of comet assay were used for the measurement of 
DNA damage or oxidative DNA damage and we also validated a modification of comet assay 
for measuring DNA crosslinks. This evaluation was carried out either in vitro in HeLa cells 
and in peripheral blood lymphocytes from healthy donors from Transfusion department of 
University Hospital in Hradec Kralove and also in peripheral lymphocytes of patients with 
non-small cell lung cancer treated with platinum derivatives in the Pulmonary department in 
University Hospital in Hradec Kralove. Oxidative damage to DNA were also measured by 
ELISA where we evaluated the level of 8-OHdG in urine of patients. 
At first we validated the comet assay method for the measurement of DNA crosslinks 
using a mutagen styrene oxide as a DNA breaking agent. The method was calibrated in in 
vitro conditions on HeLa cells and human lymphocytes from healthy donors. We have 
demonstrated that we are able to use this method to detect a cisplatin dose-dependent 
formation of DNA crosslinks. The results were subsequently verified in in vivo conditions in 
which we found that despite the considerable inter-individual differences, we are able to detect 
changes in induction and repair of DNA crosslinks in patients during chemotherapy. Further 
we evaluated DNA damage and repair by measuring single-strand breaks, DNA crosslinks and 
changes in the levels of DNA repair capacity (base and nucleotide excision repair) during 
chemotherapy. Then we focused on changes in levels of oxidative DNA damage during 
chemotherapy. We also compared input values of DNA damage and repair of patients and 
values of age-corresponding healthy controls. When comparing patients and controls, level of 
base excision repair was significantly higher in the control group, while the level of nucleotide 
excision repair in both groups was essentially the same. We found a significantly higher level 
of single-strand breaks immediately after administration of chemotherapy. Similarly, we found 
the highest incidence of DNA crosslinks immediately or one day after chemotherapy. We also 
found that the number of single-strand breaks increases throughout the chemotherapy 
(although nonsignificantly) and we can also find residual DNA crosslinks that persist in DNA 
even after the whole chemotherapy. We also compared the input values of repair capacity in 
patients who finished a whole chemotherapy and patients who died during it. We got similar 
results when comparing groups of patients and controls. However, the level of base excision 
repair was higher in the group of patients who finished a whole chemotherapy, while the level 
of nucleotide excision repair in both groups was essentially the same. 
Data from our pilot study indicate that it is possible to use a modified comet assay for 
monitoring changes in the formation and repair of DNA crosslinks in vitro and in patients 
during chemotherapy treatment. Furthermore, we confirmed the results of other studies 
dealing with DNA damage during the treatment of malignant diseases and the connection of 
the lack of base excision repair efficacy as a risk factor for these diseases. Moreover, our 
results suggest that although cisplatin is removed from the DNA by nucleotide excision repair, 
base excision repair plays also a very important role in the clinical condition of the patient and 
his survival. 
 
 
 
 
 
 
 
 
 
